2019 ACR/ARP Annual Meeting*

Download All
November 8-13, 2019; Atlanta, Georgia
Review the latest RA management data with Capsule Summaries and expert-authored commentaries covering key studies from ACR 2019.
Stanley B. Cohen, MD
Jonathan Kay, MD

Rheumatoid Arthritis Highlights From ACR 2019

Slidesets Filgotinib Demonstrates Favorable Safety in Pooled Analysis of Phase III Studies in Patients With Rheumatoid Arthritis
Slidesets Impact of Hydroxychloroquine on MACE in Medicare Recipients With Rheumatoid Arthritis
Slidesets Meta-analysis: MACE and VTE Across JAK Inhibitor Studies in Patients With Rheumatoid Arthritis
Slidesets TARA: Tapering csDMARDs First vs TNF Inhibitors in Patients With RA and Very Low Disease Activity
Slidesets Phase IIb Trial of IRAK4 Inhibitor, PF-06650833, in Patients With Moderately to Severely Active RA and Inadequate Response to MTX
Slidesets SELECT-NEXT and SELECT-BEYOND: Proteonomic Analysis of Upadacitinib Mode of Action in Patients With Rheumatoid Arthritis
Slidesets SELECT Pooled Analysis: MACE and VTE Across Upadacitinib Studies in Patients With Rheumatoid Arthritis
Slidesets All-BARI-RA Updated Findings: Long-term Safety of Baricitinib in Patients With Rheumatoid Arthritis
Slidesets Pilot Study of Neurostimulation Using a Novel VNS Device for Treatment of Drug-Refractory RA
Slidesets REDO: Ultra-Low-Dose Rituximab for Continued Treatment of RA in Patients on Stable Treatment With Rituximab

ClinicalThought

MACE and VTE data were presented for all approved and phase III JAK inhibitors.

Stanley B. Cohen, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 5, 2019 Expired: December 4, 2020

Here’s how new strategies like ultralow-dose rituximab, a novel small molecule IRAK-4 inhibitor, and vagus nerve stimulation may or may not change clinical practice.

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: January 9, 2020 Expired: January 8, 2021
Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo
Contact Info

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Mallinckrodt Pharmaceuticals

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue